AI Article Synopsis
- This systematic review and meta-analysis investigates the effectiveness and safety of rituximab (RTX) for treating idiopathic inflammatory myositis (IIM) by analyzing multiple studies through a systematic search of PubMed and Embase.
- Seventeen studies involving 362 patients were included, revealing an overall response rate of 70%, with complete remission in 13% and partial response in 48%, indicating significant variation among different myositis types.
- While RTX shows promise for IIM treatment, the notable side effects, including infusion reactions and infections, underscore the necessity for careful patient monitoring and further controlled trials to better understand long-term effects and establish treatment protocols.
Article Abstract
Objective: This systematic review and meta-analysis assess the efficacy and safety of rituximab (RTX) in treating idiopathic inflammatory myositis (IIM).
Methods: PubMed and Embase were systematically searched for trials and observational studies involving RTX use in IIM. Data were analyzed using a random-effects model to generate pooled estimates for overall response, complete remission, partial response, and adverse events, with subgroup analyses by myositis type and RTX dosage (PROSPERO registered number CRD42022353740). Risk of bias assessments were done using the Newcastle-Ottawa Scale for observational studies and risk of bias 1 tool for trials.
Results: Seventeen studies (1 randomized controlled trial and 16 observational studies), encompassing 362 patients, were included. The overall pooled response rate was 70% (95% confidence interval [CI]: 57%-82%; I2 = 74%, p < 0.001). Complete remission occurred in 13% (95% CI: 3%-25%; I2 = 79%, p < 0.001) and partial response in 48% (95% CI: 30%-67%; I2 = 87%, p < 0.001), both with significant heterogeneity. Subgroup analysis revealed high response rates across all myositis types: polymyositis 69%, dermatomyositis 67%, antisynthetase syndrome 70%, juvenile dermatomyositis 60%, and immune-mediated necrotizing myopathy 86%. Response rates were similar between RTX induction doses of 1 g IV on days 0 and 14 (68%) and 375 mg/m 2 weekly for 4 weeks (71%). Reported adverse events totaled 120, including infusion reactions (18.5%) and infections (12.4%).
Conclusions: RTX shows a favorable clinical response in IIM treatment, though response rates vary. There was a significant heterogeneity in treatment effect estimates that are based on a small number of patients. The incidence of infusion reactions and infections highlights the need for careful monitoring. Further controlled trials are essential to refine treatment protocols and evaluate long-term outcomes for RTX's role in IIM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0000000000002151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors Associated With the Development of Calciphylaxis in Patients With Chronic Kidney Disease: A Systematic Review.
Cureus
December 2024
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Calciphylaxis is a rare but potentially life-threatening disease that is not yet completely understood. It occurs mainly in patients with chronic kidney disease termed calcific uremic arteriolopathy (CUA) but also affects patients with normal renal function. Although this disease's pathogenesis is unclear, it is associated with the dysregulation of calcium and phosphate and subsequent calcification of peripheral arterioles.
View Article and Find Full Text PDFMetabolic syndrome is associated with breast cancer mortality: A systematic review and meta-analysis.
J Intern Med
January 2025
Department of Oncology, Aarhus University Hospital/Aarhus University, Aarhus, Denmark.
Background: This systematic review and meta-analysis assesses the association between metabolic syndrome and breast cancer (BC) outcomes in BC survivors.
Methods: Systematic searches were carried out in PubMed and Embase using variations of the search terms: breast neoplasms (population), metabolic syndrome (exposure), and survival (outcome). Metabolic syndrome was characterized according to the American Heart Association, which includes the presence of three out of five abnormal findings among the risk factors: high blood pressure, high triglycerides, low high-density lipoprotein, high fasting glucose, and central obesity.
Relationship between periodontitis and systemic diseases: A bibliometric and visual study.
Periodontol 2000
January 2025
Department of Periodontology, University of Bern, Bern, Switzerland.
To provide a comprehensive and updated mapping of observational studies assessing the relationship between periodontitis and systemic diseases through a bibliometric and visual analysis. A search was conducted using the Web of Science database, covering the period 1989 to 2024. The Medical Subject Headings (MeSH) from the US National Library of Medicine was used to categorize systemic conditions, focusing on terms unrelated to stomatognathic diseases.
View Article and Find Full Text PDFImpact of biologics on stoma creation and reversal in Crohn's disease: a retrospective analysis from 2007 to 2021.
Tech Coloproctol
January 2025
Department of General Surgery, Jinling Hospital, Nanjing Medical University, No. 305 East Zhongshan Rd, Nanjing, 210002, People's Republic of China.
Background: Trends of stoma creation at index surgery for Crohn's disease (CD) in the biologics era has not been thoroughly investigated. This study aimed to assess the impact of increasing biologics use on stoma rates at index surgery of CD, as well as identifying risk factors for the creation and nonreversal of CD-related stoma.
Methods: In this single-center retrospective analysis, consecutive CD patients who underwent index bowel surgery from 2007 to 2021 were reviewed.
Association between sarcopenic obesity and risk of frailty in older adults: a systematic review and meta-analysis.
Age Ageing
January 2025
School of Nursing, Jilin University, Changchun, China.
Background: Age-related changes in body composition such as muscle loss can lead to sarcopenia, which is closely associated with frailty. However, the effect of body fat accumulation on frailty in old age remains unclear. In particular, the association between the combination of these two conditions, known as sarcopenic obesity, and frailty in older adults is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!